Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report sent to investors on Thursday.

A number of other analysts have also recently commented on RGEN. Evercore ISI began coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Finally, Royal Bank of Canada cut their price objective on Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a research note on Wednesday, April 30th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Repligen Price Performance

Shares of RGEN opened at $123.24 on Thursday. The company has a market capitalization of $6.92 billion, a P/E ratio of -241.65, a P/E/G ratio of 4.54 and a beta of 1.21. The business’s 50-day moving average is $135.03 and its two-hundred day moving average is $145.37. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same period in the previous year, the business posted $0.28 EPS. The business’s revenue was up 10.4% compared to the same quarter last year. Research analysts predict that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the period. Groupama Asset Managment lifted its position in shares of Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Repligen in the fourth quarter valued at approximately $53,428,000. Finally, Raymond James Financial Inc. purchased a new stake in Repligen during the 4th quarter worth approximately $52,492,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.